Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease

Journal of Clinical Oncology

Volumn 27, Issue 24, 2009, Pages 3923-3928

  D'Amico, Anthony V ^a   Moran, Brian J ^a   Braccioforte, Michelle H ^a   Dosoretz, Daniel ^a   Salenius, Sharon ^a   Katin, Michael ^a   Ross, Rudi ^a   Chen, Ming Hui ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CESIUM 131; GONADORELIN AGONIST; IODINE 125; PALLADIUM 103; RADIOISOTOPE; GONADORELIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; COHORT ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME; BRACHYTHERAPY; DRUG POTENTIATION; MORTALITY; PROBABILITY; PROSTATE TUMOR;

AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; COMBINED MODALITY THERAPY; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROBABILITY; PROSTATIC NEOPLASMS;

EID: 69849103003     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.3992     Document Type: Article

References (46)

1. Denham J, Steigler A, Lamb DS, et al: Shortterm androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Tran-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6:841-850, 2005
2. Pilepich MV, Winter K, John MJ, et al: Phase III Radiation Therapy Oncology Group (RTOG) 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50:1243-1252, 2001
3. D'Amico AV, Manola J, Loffredo M, et al: 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292:821-827, 2004
4. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 360:103-106, 2002
5. Pilepich MV, Winter K, Lawton CA, et al: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61:1285-1290, 2005
6. Zelefsky MJ, Moughan J, Owen J, et al: Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer. Int J Radiat Oncol Biol Phys 59:1053-1061, 2004
7. Beyer DC, McKeough T, Thomas T: Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61:1299-1305, 2005
8. Zelefsky MJ, Kuban DA, Levy LB, et al: Multiinstitutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67:327-333, 2007
9. Pellizzon AC, Salvajoli J, Novaes P, et al: The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition. Int J Med Sci 5:113-120, 2008
10. Potters L, Morgenstern C, Calugaru E, et al: 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 179:S20-S24, 2008 (suppl)
11. Nobes JP, Wells IG, Khaksar SJ, et al: Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: The Guildford experience. Prostate Cancer Prostatic Dis 12:61-66, 2009
12. Franca CA, Vieira SL, Bernabe AJ, et al: The seven-year preliminary results of brachytherapy with Iodine-125 seeds for localized prostate cancer treated at a Brazilian single-center. Int Braz J Urol 33:752-762, 2007
13. Cesaretti JA, Stone NN, Skouteris VM, et al: Brachytherapy for the treatment of prostate cancer. Cancer J 13:302-312, 2007
14. Dattoli M, Wallner K, True L, et al: Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer 110:551-555, 2007
15. Lee WR, Sharkey J, Cowan JE, et al: Prostate brachytherapy: A descriptive analysis from CaPSURE. Brachytherapy 6:123-128, 2007
16. Merrick GS, Butler WM, Wallner KE, et al: Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam. Int J Radiat Oncol Biol Phys 68:34-40, 2007
17. Sylvester JE, Grimm PD, Blasko JC, et al: 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy: Seattle experience. Int J Radiat Oncol Biol Phys 67:57-64, 2007
18. Khaksar SJ, Laing RW, Henderson A, et al: Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy. BJU Int 98:1210-1215, 2006
19. Stock RG, Ho A, Cesaretti JA, et al: Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Int J Radiat Oncol Biol Phys 66:389-394, 2006
20. Vargas CE, Martinez AA, Boike TP, et al: High-dose irradiation for prostate cancer via a highdose-rate brachytherapy boost: Results of a phase I to II study. Int J Radiat Oncol Biol Phys 66:416-423, 2006
21. Yoshioka Y, Konishi K, Oh RJ, et al: High-doserate brachytherapy without external beam irradiation for locally advanced prostate cancer. Radiother Oncol 80:62-68, 2006
22. Guedea F, Aguilo F, Polo A, et al: Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1-T2 prostate cancer. Radiother Oncol 80:57-61, 2006
23. Vargas C, Martínez A, Galalae R, et al: Highdose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features. Prostate Cancer Prostatic Dis 9:245-253, 2006
24. Merrick GS, Wallner KE, Butler WM, et al: Permanent prostate brachytherapy: Is supplemental external-beam radiation therapy necessary? Oncology 20:514-522, 2006
25. Stone NN, Potters L, David BJ, et al: Multicenter analysis of effect of high biologically effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 73:341-346, 2009
26. Greene FL: Prostate, in Greene FL, Page DL, Fleming ID, et al (eds): AJCC Cancer Staging Manual (ed 6). New York, NY, Springer, 2002, pp 309-316
27. Cooperberg MR, Cowan J, Broering JM, et al: High-risk prostate cancer in the United States, 1990-2007. World J Urol 26:211-218, 2008
28. Agresti A (ed): An Introduction to Categorical Data Analysis (ed 2). New York, NY, John Wiley & Sons, 2002, pp 16-52
29. Hollander M, Wolfe DA (eds): Nonparametric Statistical Methods (ed 2). New York, NY, John Wiley & Sons, 1999, pp 189-269
30. Fine JP, Gray RJ: A proportional hazards model for the sub distribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
31. Klein JP, Moeschberger ML: Semiparametric proportional hazards regression with fixed covariates, in Klein JP, Moeschberger ML (eds): Survival Analysis: Techniques for Censored and Truncated Data (ed 2). New York, NY, Springer, 2003, pp 243-293
32. Lee WR, deGuzman AF, Bare RL, et al: Postbrachytherapy analysis of transperineal interstitial permanent prostate brachytherapy: Evidence for a learning curve in the first year at a single institution. Int J Radiat Oncol Biol Phys 46:83-88, 2000
33. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998
34. Gaynor JJ, Feuer EJ, Tan CC, et al: On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 88:400-409, 1993
35. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
36. Neter J, Wassermann W, Kutner M (eds): Simultaneous inferences and other topics in regression analyses-1, in Applied Linear Regression Models. Homewood, IL, Irwin, 1983, pp 150-153
37. Oefelein MG: Time to normalization of serum testosterone after 3-month luteinizing hormonereleasing hormone agonist administered in the neoadjuvant setting: Implications for dosing schedule and neoadjuvant study consideration. J Urol 160: 1685-1688, 1998
38. Gulley JL, Figg WD, Steinberg SM, et al: A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on randomized phase III clinical trials using limited hormonal therapy. J Urol 173:1567-1571, 2005
39. D'Amico AV, Renshaw AA, Loffredo B, et al: Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer 110:1723-1728, 2007
40. Sohayda C, Kupelian PA, Levin HS, et al: Extent of extracapsular extension in localized prostate cancer. Urology 55:382-386, 2000
41. Davis BJ, Pisansky TM, Wilson TM, et al: The radial distance of extraprostatic extension of prostate carcinoma: Implications for prostate brachytherapy. Cancer 85:2630-2637, 1999
42. Zietman AL, Prince EA, Nakfoor BM, et al: Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: Experimental and clinical results. Urology 49:74-83, 1997 (suppl)
43. Bill-Axelson A, Holmberg L, Ruutu M, et al: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977-1984, 2005
44. Sanda MG, Dunn RL, Michalski J, et al: Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250-1261, 2008
45. Wu AK, Cooperberg MR, Sadetsky N, et al: Health Related quality of life I patients treated with multimodal therapy for prostate cancer. J Urol 180: 2415-2422, 2008
46. Wallner K, Merrick G, True L, et al: 125I versus 103Pd for low risk prostate cancer: Preliminary PSA outcomes from a prospective randomized ulticenter trial. Int J Radiat Oncol Biol Phys 57:1297-1303, 2003